Aggressive neoplastic plasma cell growth with MLL gene rearrangement after high-dose therapy with autologous stem cell support for multiple myeloma.
We report a case of a patient with IgA kappa multiple myeloma (MM) mobilized with etoposide and subsequently receiving high-dose melphalan (HDM) with stem cell support. She relapsed rapidly post transplantation. Southern blot and fluorescent in situ hybridization analysis showed MLL gene rearrangement in the myeloma cells, which was not detected in the sample at diagnosis or in the PBSC harvested with etoposide plus G-CSF. These observations suggest that clonal rearrangement of the MLL gene is caused by etoposide. Patients with MM undergoing HDM with stem cell rescue may be at an increased risk of not only secondary leukemia, but also secondary genetic abnormalities in myeloma cells, especially those receiving priming with etoposide for peripheral blood stem cell collection.
Nishii
K
K
The Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Mie, Japan.
Katayama
N
N
Chen
F
F
Usui
E
E
Kadowaki
S
S
Mitani
H
H
Masuya
M
M
Kageyama
S I
SI
Kita
K
K
Shiku
H
H
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002455:Cell Division / Q000187:drug effects; D020732:Cytogenetic Analysis; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D015321:Gene Rearrangement / Q000187:drug effects; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D010950:Plasma Cells / Q000187:drug effects / Q000473:pathology; D012008:Recurrence; D014182:Transplantation, Autologous
D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide